Neurophth Closes RMB 400 Million Series B Financing

– Neurophth Biotechnology Ltd. announced the closing of a RMB 400 million ($61.9 million USD) Series-B financing with a premier syndicate of investors, co-led by Guofang Capital and InnoVision Capital.
– Neurophth is a fully-integrated genetic medicines company developing AAV-delivered gene therapies for the treatment of ocular diseases.
– The company has an extensive portfolio of potentially curative gene therapies for the treatment of ocular genetic diseases.